<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clonal disorders of hematopoiesis, such as <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>), affect both hematopoietic stem cells and progenitor cells within the erythroid, platelet and granulocytic lineages and can have devastating consequences in children and adults </plain></SENT>
<SENT sid="1" pm="."><plain>The genetic features of these diseases often include clonal, nonrandom chromosomal deletions (e.g., 7q-, 5q-, 20q-, 6q-, 11q- and 13q-) that appear to inactivate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes required for the <z:mpath ids='MPATH_458'>normal</z:mpath> development of myeloid cells (reviewed in Bench and Fenaux) </plain></SENT>
<SENT sid="2" pm="."><plain>These putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressors have proved to be much more difficult to identify than oncogenes activated by chromosomal translocations, the other major class of chromosomal lesions in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Although <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> are almost certainly caused by mutations in stem/progenitor cells, the role of inactivated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes in this process remains poorly understood </plain></SENT>
<SENT sid="4" pm="."><plain>In a small portion of myeloid diseases, mutations have been identified in genes encoding factors known to be required for <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis, such as PU.1, RUNX1, CTNNA1 (alpha-catenin) and c/EBPalpha, and implicating these genes as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressors </plain></SENT>
<SENT sid="5" pm="."><plain>Nonetheless, the identities of most deletion-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressors in these diseases remains elusive, despite complete sequencing of the human genome </plain></SENT>
<SENT sid="6" pm="."><plain>The deleted regions detected by cytogenetic methods are generally very large, containing many hundreds of genes, thus making it hard to locate the critical affected gene or genes </plain></SENT>
<SENT sid="7" pm="."><plain>It is also unclear whether dysfunctional myelopoiesis results from haploinsufficiency, associated with the deletion of one allele, or from homozygous inactivation due to additional point mutations or microdeletions of the retained <z:mp ids='MP_0002169'>wild-type</z:mp> allele </plain></SENT>
<SENT sid="8" pm="."><plain>In general <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> have proved surprisingly resistant to conventional treatments </plain></SENT>
<SENT sid="9" pm="."><plain>Targeted therapeutic advances in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> will likely depend on a full comprehension of underlying molecular mechanisms, in particular the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes lost through clonal, nonrandom chromosomal deletions, such as the 7q- and (del)5q </plain></SENT>
</text></document>